Dutch consensus: CYP2D6 genotype '1-0' classified as intermediate metabolizer;Nederlandse consensus: CYP2D6 genotype '1-0' ingedeeld als intermediaire metaboliseerder

Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde

Volumn 33, Issue 1, 2008, Pages 52-53

  Van Schaik, R H N ^a,b   Grandia, L ^c   De Goede, A ^c   Bet, P M ^d   Bekers, O ^e   Guchelaar, H J ^f   Goldschmidt, H M J ^b   Meijer, M M C ^g   Mulder, H ^h   Van Der Weide, J ^b,i   Deneer, V H M ^b,j  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Task Force Farmacogenetica NVKC ^*

^c Royal Dutch Association for the Advancement of Pharmacy   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Roche Diagnostics Nederland BV   (Netherlands)

^h Wilhelmina Ziekenhuis   (Netherlands)

ⁱ Klinisch Chemisch Laboratorium Ziekenhuis Sint Jansdal Harderwijk

^j Apotheek Sint Antonius Ziekenhuis Nieuwegein

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

GENOTYPE; HUMAN; LABORATORY TEST; METABOLISM; NETHERLANDS; PHARMACOGENETICS; SHORT SURVEY;

EID: 38949195784     PISSN: 15708306     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-73.
2. Luo HR, Gaedigk A, Aloumanis V, Wan YJ. Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol 2005; 61: 797-802.
3. AmpliChip CYP450 Test Roche Diagnostics: www.amplichip.com
4. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 2004; 369: 23-37.
5. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95.
6. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002; 72: 76-89.
7. Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, Leon J de, Koch WH, Wedlund PJ. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003; 49: 542-51.
8. Dalén P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999; 9: 697-706.
9. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B, Roots I. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-52.
10. Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12: 571-80.
11. Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmöller J. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23: 459-66.
12. Steimer W, Zöpf K, Amelunxen S von, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50: 1623-33.